Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.
about
Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemiaDendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytesAdvances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerTherapeutic cancer vaccines: past, present, and futureImmunotherapy for colorectal cancerTrial watch: Dendritic cell-based anticancer therapyThe emerging role of immunotherapy in colorectal cancerMechanisms of action of therapeutic antibodies for cancerAn efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinomaInterferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.Colorectal cancer immunotherapy.New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targetsEfficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model.Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.Monoclonal antibodies: versatile platforms for cancer immunotherapy.T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.Recent advances in dendritic cell vaccines for cancer treatment.Translating tumor antigens into cancer vaccinesCell-based therapy approaches using dying cells: from tumour immunotherapy to transplantation tolerance induction.Strategies for designing and optimizing new generation vaccines.Immune complex-mediated antigen presentation induces tumor immunity.Principles of tumor immunosurveillance and implications for immunotherapy.Protection and compensation in the influenza virus-specific CD8+ T cell responseCurrent immunotherapeutic approaches in pancreatic cancer.Some interfaces of dendritic cell biology.Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells.Memories of virus-specific CD8+ T cells.B7-H1-targeted immunotherapy for head and neck cancer.Dendritic cells as therapeutic vaccines against cancer.Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cellsOn the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunityAntitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.Trial watch: Dendritic cell-based interventions for cancer therapyDendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivoCombinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.Taming cancer by inducing immunity via dendritic cells.GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer.
P2860
Q24800882-54E13D58-5027-4110-8AD3-9C12202DFFA1Q24806024-E8B8DE62-0220-4121-921B-8BA6E5CE7014Q26749451-C510F24F-B9C2-4579-820F-9D0C8F5E28F9Q26863283-BC5936B8-FC1D-4ACC-89CD-ADBC2C18594CQ27021837-9EEEA683-0088-4B06-99CC-7226DF732D6DQ27024047-19AFAC7D-931E-4875-B8A4-035F4106347AQ28067898-2FB92A80-0E70-4E70-ABC6-F6BF47AB5118Q28385366-C08053B3-7FBC-4409-8139-D6D4615BCFB1Q28749871-B96D3374-FC2D-41FE-92BA-574BCFDC95DAQ30811481-90542A8B-3247-495C-AD0A-84BD1236ABB1Q33701465-003B38AF-2D87-445D-BCFF-0A712FB89591Q33731804-583B640F-5252-4EBE-AD64-0BA554117275Q33772145-6C8074C4-1B3A-45D0-9982-DA98ED0F1ED2Q33892712-CA5A9762-A948-477D-B83E-30E06CA30288Q33897693-5E23A30C-5C8A-4CDD-ACEC-B1FDAF6B4612Q34111693-D1B4070D-006C-400F-B088-460E785A6D89Q34191186-0938925F-75BD-4F8D-BBF2-6E0BA9ED59C4Q34480504-A3FF9BD7-F2BB-49CD-AAD9-3E05AA8A7FFFQ34484042-AC779834-2ECD-4BE0-8F79-3E0FE925BBD9Q34560654-DC7F0CD8-D463-454A-BB4A-B2E95119A706Q34572198-DA3278DF-405D-4992-9604-61CE6BA4E272Q34793164-67B79DAF-14A9-4AB4-89D5-800994B4E4C2Q35043113-BC48755F-0453-4170-9E3D-C21F327ADD25Q35163418-EA34458F-496C-43E4-9A25-1D9FBCDF98DFQ35212837-415B2AB7-7203-4825-9B10-CAD6FA07C3B2Q35219290-5ECB389E-58C2-4EA2-8320-5A4A1D29997CQ35633683-E681B5D4-728C-4B6D-9A21-877197C1DC84Q35734111-7BFDB1D2-EFCC-4845-A7A2-165BE2D51214Q35907010-449854E0-D7C8-4E62-8786-168CDEB756A9Q36085614-55019ED3-28B8-4470-A647-7234D0D171B0Q36190053-65110452-F2E6-4C27-A7C2-65E9018C1F03Q36369467-3B0E4492-7FAB-4ACE-B974-35CE90ABAA10Q36370816-99FF2E61-8E1E-45EE-9C6A-54FECE7F6C7FQ36376481-4C7FC98B-0DC9-40D2-858D-C535BE87C68DQ36388529-CD5A1BCA-376C-47BC-A8B7-A4242CCBFD2AQ36407174-142533FC-346E-4404-BF0A-8F9CD86729A2Q36422849-B3A8F02A-FECC-4BBC-BDB0-AD96F117E8C4Q36908547-569AF210-8603-4AE5-98FC-ADFD6A14280FQ36990604-073083DC-0683-47A0-828E-C173DE226A4FQ37012084-04534F9A-17D3-4CC7-9A17-927AED18B3FB
P2860
Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Cross-priming of naive CD8 T c ...... led allogeneic melanoma cells.
@ast
Cross-priming of naive CD8 T c ...... led allogeneic melanoma cells.
@en
type
label
Cross-priming of naive CD8 T c ...... led allogeneic melanoma cells.
@ast
Cross-priming of naive CD8 T c ...... led allogeneic melanoma cells.
@en
prefLabel
Cross-priming of naive CD8 T c ...... led allogeneic melanoma cells.
@ast
Cross-priming of naive CD8 T c ...... led allogeneic melanoma cells.
@en
P2093
P2860
P50
P356
P1476
Cross-priming of naive CD8 T c ...... lled allogeneic melanoma cells
@en
P2093
A K Palucka
E M Neidhart-Berard
J C Cerottini
M Nouri-Shirazi
P2860
P304
P356
10.1084/JEM.192.11.1535
P407
P577
2000-12-01T00:00:00Z